Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...

When the fledgling Indian government drafted its higher education policy after Independence, it formed two separate tiers for teaching and research: colleges and universities in one, exclusive research establishments in the other. The intention was of the noblest, to deploy our best talent exclusively to create an indigenous knowledge pool; in particular, to provide research input for the nation’s development. Sixty years down the line, the outcome has patently failed those...

-Economic and Political Weekly The compulsory licence for Nexavar is only the beginning of a new battle over drug prices. The grant of a compulsory licence (CL) to Natco Pharma, a relatively small Indian pharmaceutical company, to manufacture and sell the cancer drug sorafenib (Nexavar) has been rightly hailed as a major step forward for public health and the wider availability of life saving medicines.   The German pharmaceutical company Bayer holds the patent...

The Supreme Court has handed down an extraordinary decision with some extraordinary arguments directing the central government to execute the “river interlinking project”. How could the Court which says “it can hardly take unto itself tasks of making of a policy decision or planning for the country on the need for acquisition and construction of river linking channels” then go on to actually take the very same policy decision and...

India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving medicines at much cheaper cost than by obtaining the medicine from...